Abstract
Dupilumab is currently the only biologic treatment approved for moderate-to-severe atopic dermatitis (AD). Though limited, available clinical data describing dupilumab use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. According to the position paper from the European Task Force on Atopic Dermatitis, systemic treatment in pregnant women with AD should be restricted to corticosteroids, cyclosporine and azathioprine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
